Biotricityโs latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care.
REDWOOD CITY, Calif., Mar 12, 2025 (GLOBE NEWSWIRE) โ Biotricity Inc. (OTCQB:BTCY), (โBiotricityโ or the โCompanyโ), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the companyโs total to 15 issued patents, with an additional 14 patents pending. The expansion of the companyโs IP portfolio underscores Biotricityโs commitment to advancing and improving the patient journey. By streamlining diagnostic processes, Biotricity helps medical providers detect potential health issues earlier, improving patient outcomes while also reducing the burden on the stressed healthcare system.
Biotricityโs newest group of patents represents a breakthrough in remote patient monitoring technology, with a focus on multi-sensor patch devices capable of collecting various biometrics. These innovations are centered on a versatile device platform with base components that can be inserted into a patch form factor, then removed and placed into a watch form factor. This adaptable design ensures wider integration and compliance for different patient needs and clinical applications.
This group of patents will drive Biotricityโs next-generation device which could enable multiple diagnostic studies to be conducted simultaneously. For instance, patients needing a cardiac and sleep study would traditionally have to navigate fragmented care pathways, schedule multiple appointments, and endure long wait times. With Biotricity, these critical diagnostic assessments could be performed concurrently with the same device, reducing delays in diagnosis and expediting treatment.
โAt Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home.โ said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. โOur solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.โ
โAs part of our R&D strategy, we continue to mindfully develop a robust, diversified IP portfolio that integrates patents, trade secrets, FDA clearances, and trademarks, while ensuring each product or technology is aligned with reimbursement and clinical outcomes. We expect to secure further patents this year and next. By expanding our IP portfolio, we are not only reinforcing our leadership in the industry but also ensuring that our technology remains at the forefront of innovation.โ
For more information Biotricity and its state-of-the art suite of remote patient monitoring solutions, please visit www.biotricity.com or contact investors@biotricity.com.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricityโs unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words โmay,โ โshould,โ โwould,โ โwill,โ โcould,โ โscheduled,โ โexpect,โ โanticipate,โ โestimate,โ โbelieve,โ โintend,โ โseek,โ โproject,โ or โgoalโ or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Companyโs other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Companyโs future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Companyโs current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Companyโs inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Companyโs inability to expand the Companyโs business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Companyโs failure to implement the Companyโs business plans or strategies. These and other factors are identified and described in more detail in the Companyโs filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
